Malignant Mesothelioma Pipeline Landscape Analysis, 2024 - Incyte's INCB001158 and Polaris' Pegargiminase Lead the Way in Mechanism-Specific Interventions

The Continuous Battle Against Malignant Mesothelioma Advances in Therapeutic Solutions and Key Players Enhancing Patient Outcomes Through Innovation | --- | --- | |-------------------------|-------------------------| | | | | Epizyme Ys Therapeutics | | | Novartis | | | Bayer | | | RS Oncology | | | | Polaris Pharmaceuticals | | Merck | | | Vivace Therapeutics | | | Shionogi | | | Mirati Therapeutics | | | Incyte Corporation | | | TCR2 Therapeutics | | | SOTIO Biotech | | | Pfizer | | | Ascentage Pharma | | ...